Tricyclics (TCAs)

Desipramine

Imipramine

Imipramine

Imipramine

Charney et al.

(13)

Reimherr et

al. (86)

Peselow et al.

(74)

McGrath et al.

(58)

11 UP inpatients (DMI;

2.5 mg/kg)

27 UP outpatients (IMI;

150-300 mg)

15 UP outpatients (IMI;

150-300 mg)

UP outpatients, n = 22

atypical depression

(IMI: 150-300 mg/day)

TCAs (by history), open

label

TCAs (by history),double

blind

Paroxetine, double blind

crossover

Pheneizine (60-90), double

blind crossover

1 of 11 (9%) responders

8 of 27 (30%) responders

11 of 15 (73%) responders

9 of 22 (41%) responders

Approved Heterocyclics

(HCAs)

Bupropion

Nomifensine

Stern et al.

(100)

Nolen et al.

(69)

Schmauss et

al. (92)

30 UP inpatients (BUP,

675 mg/d; n = 19;

PBO, n = 11); 4 weeks

55 UP outpatients, > 2

wks of BUP, 350 mg

10 UP inpatients

20 Recurrent UP and BP

inpatients

TCAs (by history), placebo

controlled

IMI, double blind 4 week

controlled trial, followed

by open label BUP

TCAs (by history), double

blind crossover vs.TCP

TCAs (by history), open

label

BUP significantly better than PBO

on CGI and HRSD (response

rate not reported )

Significant improvement in both

intolerant (n = 18) and

resistant (n = 38) patients on

CGI and HRSD (response

rate not reported)

1 of 10 (10%)

4 of 20 (20%) (pooled; po, 30%,

n = 10; iv, 10%, n =10)

Trazodone

Cole et al.

(14)

25 outpatients (mixed UP,

BP) TRAZ: 264 mg.

TCAs (by history), open

lable

14 of 25 (56%) responders

Trazodone

Oxaprotiline

Cole et al.

(14)

Nolen et al.

(68)

25 outpatients (mixed UP,

BP) TRAZ: 264 mg.

Initial drug: n = 33, UP

inpatients (260 mg);

crossover: n = 31, UP

inpatients (267 mg)

TCAs (by history), open

label

TCAs (by history), double

blind; TCAs (by history) +

FLV, double blind

crossover

9 of 33 (27%)

12 of 31 38%

}

pooled: 33%
responders

SRIs

Fluoxetine

Reimherr et

al. (86)

40 UP outpatients FLU:

60-80 mg/d

35 UP outpatients FLU:

60-80 mg/d

TCAs (by history), double

blind

Confirmed TCA

nonresponse, double blind

17 of 40 (43%) responders

18 of 35 (51%) responders

Fluoxamine

Beasley et al.

(7)

Nolen et al.

(69)

Initial drug: n = 35, UP

inpatients (288 mg);

crossover: n = 21, UP

inpatients (286 mg)

TCAs (by history), double

blind TCAs (by history) +

OXAP, double blind

0 of 35 (0%)

2 of 21 (10%)

}

 pooled: 2 of 56
(4%) responders

Paroxetine

Viqualine

Delgado et al.

(20)

White et al.

(117)

Peselow et al.

(74)

Gagiano et al.

(34)

Faravelli et al.

(28)

28 UP; inpatients (n =

21), outpatients (n = 7)

12 UP outpatients FLV:

50-300 md/d

10 UP outpatients

PAR: 30-50 mg/d

28 UP outpatients;

PAR: 30 mg/d

20 UP outpatients

TCAs (by history), open

label

DMI 150-300 mg/d, 6

weeks; double blind

crossover

IMI 150- 250 mg/d, 6

weeks; double blind

crossover

TCAs (13 by history, 15

AMI), open label

TCA {ewc MVIMG, MVIMAGE,!greateq.bmp} 150 mg > 4 weeks,

double blind crossover

Pooled: 8 of 28 (28%) responders

Inpatients: 14% (3/21)

Outpatients: 71% (5/7)

9 or 12 (75%) responders

5 of 10 (50%) responders

18 of 28 (64%) responders

5 of 10 (50%) VIQ

0 of 10 (0%) PBO

VIQ > PBO